CIK 0000275053 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in UT · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Revenue (USD) | 480.1 M | 445.3 M | 421.9 M |
| Net income (USD) | 19.5 M | 15.1 M | -390000 |
| Diluted EPS (USD/shares) | 1.06 | 0.77 | -0.02 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-09-15 | 4 | FORM 4 | 2026-09-02 |
| 2026-09-14 | 3 | FORM 3 | 2026-09-01 |
| 2026-09-03 | 4 | FORM 4 | 2026-09-01 |
| 2026-08-19 | 4 | PRIMARY DOCUMENT | 2026-08-17 |
| 2026-08-10 | 4 | PRIMARY DOCUMENT | 2026-08-06 |
| 2026-08-10 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-06 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-06 | 8-K | 8-K items 2.02,5.02,9.01 | 2026-08-06 |
| 2026-06-29 | 4 | FORM 4 | 2026-06-26 |
| 2026-06-15 | 4 | FORM 4 | 2026-06-12 |
| 2026-06-11 | 4 | FORM 4 | 2026-06-05 |
| 2026-06-03 | 4 | FORM 4 | 2026-06-01 |
| 2026-05-22 | 4 | FORM 4 | 2026-05-21 |
| 2026-05-20 | 4 | FORM 4 | 2026-05-15 |
| 2026-05-19 | 4 | FORM 4 | 2026-05-15 |
| 2026-05-19 | 4 | FORM 4 | 2026-05-15 |
| 2026-05-19 | 4 | FORM 4 | 2026-05-15 |
| 2026-05-19 | 4 | FORM 4 | 2026-05-15 |
| 2026-05-19 | 4 | FORM 4 | 2026-05-15 |
| 2026-05-19 | 4 | FORM 4 | 2026-05-15 |
| 2026-05-19 | 4 | FORM 4 | 2026-05-15 |
| 2026-05-19 | 4 | FORM 4 | 2026-05-15 |
| 2026-05-19 | 4 | FORM 4 | 2026-05-15 |
| 2026-05-19 | 4 | FORM 4 | 2026-05-15 |
| 2026-05-19 | 4 | FORM 4 | 2026-05-15 |
Forms on file (last 1,000): 4 614, 8-K 128, 10-Q 46, 3 45, SC 13G/A 35, 144 19, DEF 14A 16, 10-K 15. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=NATR (0.002 USD), /gw/filings/filings?ticker=NATR&form=8-K, /gw/filings/facts?ticker=NATR&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange